Béa Fertility, a pioneering fertility tech startup, has successfully secured an impressive €2.9 million in funding to introduce its groundbreaking at-home fertility treatment to early adopters in the UK. This investment drive was led by Octopus Ventures, with participation from JamJar and Forward Partners, as well as existing investors Calm/Storm and Q Ventures. Béa Fertility’s total funding now stands at an outstanding €3.8 million, putting it on par with other successful companies such as Elvie and Mojo within Octopus Ventures’ portfolio.
Béa Treatment Kits: A New Era in Fertility Care
The fresh capital will be used to make the first Béa Treatment Kits available to the public. These kits can be purchased online via Béa’s website. The initial users will only have to pay £350 for three Intracervical Insemination (ICI) treatment cycles, with one kit delivered at the start of each menstrual cycle throughout the three-month treatment program. The program is specifically designed for individuals currently trying to conceive.
Pioneering Leaders in Fertility Tech
Founded in 2020 by femtech expert Tess Cosad and product engineer George Thomas, Béa Fertility has developed one of the first clinical-grade at-home fertility treatments to hit the UK market. The Béa Fertility Treatment Kit allows users to perform a simple fertility treatment, Intracervical Insemination (ICI), safely at home. This treatment is a revolutionary new stepping stone in the fertility pathway, offering an alternative to costly and invasive procedures like IVF and Intrauterine Insemination (IUI).
A Transformative and Inclusive Fertility Solution
Béa’s mission is to provide a transformative and inclusive fertility solution for those struggling to conceive. The company aims to broaden access to care for LGBTQ families and groups traditionally excluded from existing fertility provisions.
Tess Cosad, CEO and co-founder at Béa Fertility stated: “Fertility impacts 1 in 6 couples, yet access to fertility care is severely lacking globally. Fertility clinics have been selling the same expensive treatments for decades, yet there are a number of groups that remain underserved, including the LGBTQIA+ community, single people and parents experiencing secondary infertility. At Béa, our aim is to fill this gap by creating inclusive, clinical-grade fertility treatments that can be used at home. This latest injection of funding – from experienced investors with a proven track record of backing successful fertility and femtech businesses – will enable us to get our pioneering treatment in the hands of the people who need it most. We can’t wait for people to try it.”
Contributing to the World’s Largest At-Home Fertility Treatment Study
The first individuals to purchase a Treatment Kit will be contributing to the world’s largest at-home fertility treatment study. During this initial treatment roll-out, Béa will collect observational and efficacy data to address the data gap surrounding infertility. Over 1,000 people have already signed up to participate. The study aims to drive advancements in the development of early-stage fertility interventions and accelerate Béa’s mission to build accessible fertility treatments for all. The early results of the study will be presented at the IFFS World Congress in Athens later this year.
Kirsten Connell, Investor at Octopus Ventures, said: “At Octopus Ventures we back founders who are changing the world for the better. We invest where we can make the greatest positive impact. When it comes to starting a family there are few things in life more meaningful than this. Béa Fertility who is reimagining the fertility care pathway, was a clear vision we wanted to get behind. We’re delighted to have joined Tess and her team on this journey.”
Brian Hatton, Partner at Q Ventures, added: “We backed Tess and the Béa team at the idea stage in their 2021 pre-seed round and they have made incredible progress since. Their at home product is truly a groundbreaking new step in the fertility care pathway, and we are excited to continue to support this incredible group as they launch and scale.”
Hi, I’m Oren, founder at BIGINTRO, a content strategy agency that helps B2B companies drive growth. We develop search, social, PR, and content marketing strategies tailored to business goals. I also have a dog named Milo.